A practical reference on obesity research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
=== Aortic dissection === Fluoroquinolones can increase the rate of rare but serious tears in the aorta by 31% compared to other antibiotics. People at increased risk include those with aortic aneurysm, hypertension, certain genetic conditions such as Marfan syndrome and Ehlers–Danlos syndrome, and the elderly. For these people, fluoroquinolones should be used only when no other treatment options are available. One year after the warning announcement, prescribing behaviors were reported to have remained unchanged.
Length – the spacer can be varied in length, for example 1.9 nm (Ad), 7.2 nm (CMG2), 11.5 nm (CMG4), allowing for enhanced presentation of Functional groups at the biosurface. Optimizes 'F' presentation – The presentation of the bioactive (functional group) on a spacer reduces steric hindrance and increases the bioactive surfaces exposed and available for interactions Rigidity – the spacer can be modified to be either flexible or rigid depending upon desired characteristics Substitutions (represented by the leaves on the stalk) – the spacer can be modified both in charge, and polarity. Branches – usually the spacer is linear, but it can also be branched including specific spacing of the branches to optimize presentation and interaction of the F group. Inert – important to the design of FSL Kode constructs is the biologically inert nature of the spacer. Importantly this feature means the S-L components of the constructs are unreactive with undiluted serum. Consequently, the constructs are compatible in vivo use, and can improve diagnostic assay sensitivity by allowing for the use of undiluted serum.
By late 2011, several women were assigned to the Ohio-class ballistic missile submarine USS Wyoming. On 15 October 2013, the US Navy announced that two of the smaller Virginia-class attack submarines, USS Virginia and USS Minnesota, would have female crew-members by January 2015. In 2020, Japan's national naval submarine academy accepted its first female candidate.
Sources: en.wikipedia.org
Behr was named political commentator of the year at the 2014 Comment Awards; in 2019, he was shortlisted for same award again. Before becoming a journalist, Behr worked as a political risk analyst reporting on countries of the former Soviet Union.Since 2020 he has presented Politics on the Couch, an occasional podcast about the psychology of politics. Daniel Ben-Ami, journalist and author; has written on economic development, the world economy, financial markets and investment funds; has also used pseudonym Daniel Nassim. His work has appeared in Jewish Chronicle, Financial Times, The Guardian, The Independent, Prospect, The Sunday Telegraph and The Sunday Times and in the successor to Living Marxism, Spiked. Roger Bennett (journalist) (born 14 September 1970); journalist for Tablet (magazine) broadcaster, podcaster, and filmmaker; co-hosts Men in Blazers podcast and television show alongside Michael Davies; author Reborn in the USA: An Englishman's Love Letter to his Chosen Home; married to Vanessa Kroll, daughter of Kroll Inc. founder Jules Kroll; his brother-in-law is comedian Nick Kroll. Bennett is Jewish. Chaim Bermant (1929–1998), journalist and novelist.
== Medicinal Use == Traditional Medicine The resin of Croton lechleri, commonly known as sangre de drago, has a long history of medicinal use by indigenous peoples and is widely used in both urban and rural contexts in Peru and Ecuador, and to a lesser extent in other endemic countries.[8] For centuries, the sap has been used to cover abrasions, cuts, scratches, blisters, bites and stings to prevent bleeding, decrease inflammation, seal wounds and injuries to protect from infection. The sap dries quickly on soft, damaged tissue, forming a barrier similar in thickness to the skin removed, noted as something akin to a "second skin." Antimicrobial activity offered by the plant is further believed to offer protection to the injury. The formation of this resistant barrier is likely due to the saps ability to co-precipitate with surrounding proteins or extracellular matrix elements. The hemostatic qualities relevant in wound healing that are associated with sangre de grado are further relevant to Amazonian indigenous communities in arresting the large amounts of bleeding following childbirth. Beyond cutaneous ailments, the use of sangre de grado is taken orally for gastrointestinal disorders and irregularities including gastritis, gastric ulcers, intestinal infections, and inflammation.
He sent Signoret specimens of American grape lice, which Signoret concluded – in 1870, while he was besieged in Paris during the Franco-Prussian War – were indeed identical to French grape lice. Meanwhile, Planchon and Lichtenstein had found vines with afflicted leaves; lice that were transferred from those leaves to the roots of healthy vines attached themselves to the vines' roots as other French grape lice did. Also in 1870, Riley discovered that American grape lice wintered on American grape vines' roots, which the insects damaged, albeit less than in the case of French vines. Riley repeated Planchon and Lichtenstein's experiment using American grape vines and American grape lice, with similar results. Thus the identity of the French and American grape lice was proven. Nevertheless, for another three years, a powerful majority in France argued that Phylloxera was not the cause of vine disease; instead, vines that were already sickly became infested with Phylloxera. Thus, in their opinion, Phylloxera was merely a consequence of the "true" disease, which remained to be found. Regardless, Riley had discovered American grape varieties that were especially resistant to Phylloxera, and by 1871, French farmers began to import them and to graft French vines onto the American rootstock. (Leo Laliman had suggested importing American vines as early as 1869, but French farmers were reluctant to abandon their traditional varieties.
Sources: en.wikipedia.org
== Production == In China, the primary site of production of glass noodles is the town of Zhangxing, in Zhaoyuan, Shandong province. Historically the noodles were shipped through the port of Longkou, and thus the noodles are known and marketed as Longkou fensi (simplified Chinese: 龙口粉丝; traditional Chinese: 龍口粉絲).
== Research == Meta-analysis found an association between periodontal disease and RA, but the mechanism of this association remains unclear. Two bacterial species associated with periodontitis are implicated as mediators of protein citrullination in the gums of people with RA. Vitamin D deficiency is more common in people with rheumatoid arthritis than in the general population. However, whether vitamin D deficiency is a cause or a consequence of the disease remains unclear. One meta-analysis found that vitamin D levels are low in people with rheumatoid arthritis and that vitamin D status correlates inversely with prevalence of rheumatoid arthritis, suggesting that vitamin D deficiency is associated with susceptibility to rheumatoid arthritis. The fibroblast-like synoviocytes have a prominent role in the pathogenic processes of the rheumatic joints, and therapies that target these cells are emerging as promising therapeutic tools, raising hope for future applications in rheumatoid arthritis. Possible links with intestinal barrier dysfunction are investigated.
Cinnarizine is an antihistamine and calcium channel blocker of the diphenylmethylpiperazine group. It is prescribed for nausea and vomiting due to motion sickness or other sources such as chemotherapy, vertigo, or Ménière's disease. Cinnarizine is one of the leading causes of drug-induced parkinsonism. Cinnarizine was first synthesized as R1575 by Janssen Pharmaceutica in 1955. The nonproprietary name is derived from the cinnamyl substituent on the free nitrogen atom of the benzhydrylpiperazine core, combined with the generic ending "-rizine" for "antihistaminics/cerebral (or peripheral) vasodilators". It is not available in the United States or Canada. It has also been cited as one of the most used drugs for seasickness within the British Royal Navy.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.